JP2020500003A5 - - Google Patents

Info

Publication number

JP2020500003A5

JP2020500003A5 JP2019511427A JP2019511427A JP2020500003A5 JP 2020500003 A5 JP2020500003 A5 JP 2020500003A5 JP 2019511427 A JP2019511427 A JP 2019511427A JP 2019511427 A JP2019511427 A JP 2019511427A JP 2020500003 A5 JP2020500003 A5 JP 2020500003A5

Authority

JP

Japan

Prior art keywords

seq

nos

antibody

ssea4

antigen

Prior art date

2017-08-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims description 54
• 102000036639 antigens Human genes 0.000 claims description 54
• 108091007433 antigens Proteins 0.000 claims description 54
• 239000012634 fragment Substances 0.000 claims description 54
• 108091036078 conserved sequence Proteins 0.000 claims description 35
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
• 238000006467 substitution reaction Methods 0.000 claims description 32
• 239000008194 pharmaceutical composition Substances 0.000 claims description 28
• 206010028980 Neoplasm Diseases 0.000 claims description 25
• 238000000034 method Methods 0.000 claims description 25
• 201000011510 cancer Diseases 0.000 claims description 21
• 108020004707 nucleic acids Proteins 0.000 claims description 16
• 150000007523 nucleic acids Chemical class 0.000 claims description 16
• 102000039446 nucleic acids Human genes 0.000 claims description 16
• 239000003814 drug Substances 0.000 claims description 13
• 229940127089 cytotoxic agent Drugs 0.000 claims description 10
• 229940127121 immunoconjugate Drugs 0.000 claims description 10
• 229940124597 therapeutic agent Drugs 0.000 claims description 10
• 239000012472 biological sample Substances 0.000 claims description 8
• 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
• 239000000523 sample Substances 0.000 claims description 8
• 239000002246 antineoplastic agent Substances 0.000 claims description 6
• 150000001720 carbohydrates Chemical class 0.000 claims description 6
• 230000001225 therapeutic effect Effects 0.000 claims description 5
• 102000004127 Cytokines Human genes 0.000 claims description 4
• 108090000695 Cytokines Proteins 0.000 claims description 4
• 210000000013 bile duct Anatomy 0.000 claims description 4
• 210000000481 breast Anatomy 0.000 claims description 4
• 210000003679 cervix uteri Anatomy 0.000 claims description 4
• 210000001072 colon Anatomy 0.000 claims description 4
• 239000002254 cytotoxic agent Substances 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 210000003238 esophagus Anatomy 0.000 claims description 4
• 210000003734 kidney Anatomy 0.000 claims description 4
• 210000004185 liver Anatomy 0.000 claims description 4
• 210000004072 lung Anatomy 0.000 claims description 4
• 210000000214 mouth Anatomy 0.000 claims description 4
• 210000001672 ovary Anatomy 0.000 claims description 4
• 210000000496 pancreas Anatomy 0.000 claims description 4
• 230000005855 radiation Effects 0.000 claims description 4
• 210000002784 stomach Anatomy 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 210000004556 brain Anatomy 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 238000011277 treatment modality Methods 0.000 claims description 3
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 2
• 206010004593 Bile duct cancer Diseases 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 206010006187 Breast cancer Diseases 0.000 claims description 2
• 208000026310 Breast neoplasm Diseases 0.000 claims description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
• 102220498332 HLA class II histocompatibility antigen, DRB1 beta chain_A100R_mutation Human genes 0.000 claims description 2
• 102220536696 Hemoglobin subunit epsilon_V30I_mutation Human genes 0.000 claims description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 102220526291 N-acetylneuraminate lyase_Y94F_mutation Human genes 0.000 claims description 2
• 206010033128 Ovarian cancer Diseases 0.000 claims description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 2
• 125000005262 alkoxyamine group Chemical group 0.000 claims description 2
• 238000004458 analytical method Methods 0.000 claims description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
• 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
• 102220356295 c.92A>G Human genes 0.000 claims description 2
• 125000000837 carbohydrate group Chemical group 0.000 claims description 2
• 238000002659 cell therapy Methods 0.000 claims description 2
• 239000003795 chemical substances by application Substances 0.000 claims description 2
• 208000029742 colonic neoplasm Diseases 0.000 claims description 2
• 239000002299 complementary DNA Substances 0.000 claims description 2
• 238000012258 culturing Methods 0.000 claims description 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
• 229940079593 drug Drugs 0.000 claims description 2
• 201000004101 esophageal cancer Diseases 0.000 claims description 2
• 206010017758 gastric cancer Diseases 0.000 claims description 2
• 230000001939 inductive effect Effects 0.000 claims description 2
• 201000010982 kidney cancer Diseases 0.000 claims description 2
• 201000007270 liver cancer Diseases 0.000 claims description 2
• 208000014018 liver neoplasm Diseases 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 201000005443 oral cavity cancer Diseases 0.000 claims description 2
• 102220221341 rs149223439 Human genes 0.000 claims description 2
• 102200054160 rs28941775 Human genes 0.000 claims description 2
• 102220226502 rs749671520 Human genes 0.000 claims description 2
• 102200115851 rs79977247 Human genes 0.000 claims description 2
• 102200010049 rs869025189 Human genes 0.000 claims description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 2
• 238000001514 detection method Methods 0.000 claims 2
• 238000009472 formulation Methods 0.000 claims 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims 1
• 241000588724 Escherichia coli Species 0.000 claims 1
• 201000005619 esophageal carcinoma Diseases 0.000 claims 1
• 238000002955 isolation Methods 0.000 claims 1
• 238000002372 labelling Methods 0.000 claims 1
• 201000005296 lung carcinoma Diseases 0.000 claims 1
• 208000029565 malignant colon neoplasm Diseases 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 238000002360 preparation method Methods 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• 210000002307 prostate Anatomy 0.000 claims 1
• 238000011282 treatment Methods 0.000 claims 1
• 239000000463 material Substances 0.000 description 2
• 244000140786 Brassica hirta Species 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1